in production and distribution, but net profits are relatively low and there is a limit to market expansion. Today, global vaccine markets are virtually monopolized by five global pharmaceutical companies. In Korea, a large number of vaccines have been dependent on imports from foreign countries. If we have a large dependency on imports, we may have a delay in vaccination and an increase in vaccine prices due to the time it takes to import. Therefore, government support is essential to develop vaccines in Korea. As of 2018, the Korean government has provided support for 38 items from 10 institutions. 6 , 7 The securing of the vaccine initiative is very important because it is related to social services to support the vulnerable.
Since 2009, swine flu pandemic has enabled the production of influenza vaccine in Korea. As a result, the scope of the vaccine has been gradually expanded and the supplying amount of vaccine has been gradually increasing.
Currently, there are 57 kinds of vaccines distributed in Korea, 15 of which are manufactured and sold by 13 manufacturing and importing companies. The global vaccine market grew from US$ 35.2 billion in 2012 to US$ 52.1 billion in 2016, while the Korean vaccine market is growing from USD$ 360 million in 2012 to USD$ 496 million in 2016. 6,7 Currently, the development of Korean vaccines is predominantly focused on flu vaccines, but is expanding to other vaccines. To date, vaccines developed in Korea include not only for influenza, but also hepatitis B vaccine, Td, varicella vaccine, hemorrhagic fever with renal syndrome vaccine, and Haemophilus influenzae type B vaccine. 6 Today, the vaccine market is constantly changing, including the development of mixed vaccines, the development of new vaccines due to the emergence of new infectious diseases, and the change of vaccine formulations. The Korean government is actively supporting the plan to further strengthen various preemptive support in order to raise vaccine self-sufficiency rate from 50% in 2018 to 80% in 2022 in the future. 6,7 Government support and constant development of vaccines by Korean pharmaceutical companies are expected to broaden the scope of vaccines in the near future and contribute to the successful implementation of NIP.
